This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
by Zacks Equity Research
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
by Zacks Equity Research
AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira and Imbruvica declines.
RHHBYNegative Net Change JNJNegative Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
ABBV Seeks FDA Nod for Rinvoq Label Expansion in Alopecia Areata
by Zacks Equity Research
AbbVie files for the FDA approval of Rinvoq in alopecia areata, backed by phase III data showing strong hair regrowth and durable results.
ABBVPositive Net Change AMRNPositive Net Change CPRXPositive Net Change CSTLPositive Net Change
biotechs
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
by Zacks Equity Research
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
GSKNegative Net Change JNJNegative Net Change IONSPositive Net Change SPROPositive Net Change
biotechs earnings
AZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
by Zacks Equity Research
AstraZeneca posts Q1 earnings and revenue beat as strong product sales and oncology growth offset generic pressures in key drugs across major markets.
SNYNegative Net Change AZNNegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
by Zacks Equity Research
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.
CPRXPositive Net Change ANIPPositive Net Change NTLAPositive Net Change INDVPositive Net Change
biotechs
Amneal 2026-2027 Upside From Biosimilars Scale
by Kanishka Das
AMRX targets 2027 upside through biosimilars scale, new complex launches, and Specialty recovery after 2026 Rytary erosion pressure.
PFENegative Net Change AMRXPositive Net Change SDZNYNegative Net Change
biotechs medical
LLY Expands Oncology Pipeline With $2.3B Ajax Therapeutics Acquisition
by Zacks Equity Research
Lilly is set to acquire Ajax Therapeutics for up to $2.3B, gaining a novel JAK2 inhibitor as it ramps up oncology bets and targets unmet needs in MPN treatment.
NVSNegative Net Change BMYNegative Net Change LLYPositive Net Change CPRXPositive Net Change
biotechs
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
by Zacks Equity Research
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
VRTXPositive Net Change AGENPositive Net Change INOPositive Net Change CRSPPositive Net Change
biotechs
AMRX Valuation: What 1.69x Sales Means for Investors
by Kanishka Das
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
RDYNegative Net Change TEVAPositive Net Change AMRXPositive Net Change
biotechs medical